---
title: "Weekly Recap | Revolution Medicines -8.17%, most brokers rate it buy"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/301471554.md"
description: "Revolution Medicines (RVMD) fell 8.17% this week to close at $189.76, while the S&P 500 gained 1.15%, leaving the stock roughly 9.32 percentage points behind the benchmark. Trading was choppy: it opened Monday at $207.68 and touched a weekly high of $210.27, then slid through Tuesday and Wednesday. Thursday brought the sharpest leg down, with the low at $180.49, before a modest bounce on Friday to close at $189.76. Weekly amplitude came to 14.34%."
datetime: "2026-10-10T07:37:17.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/301471554.md)
  - [en](https://longbridge.com/en/news/301471554.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/301471554.md)
generator: "portal-rs"
---

# Weekly Recap | Revolution Medicines -8.17%, most brokers rate it buy

## The Week

Revolution Medicines (RVMD) fell 8.17% this week to close at $189.76, while the S&P 500 gained 1.15%, leaving the stock roughly 9.32 percentage points behind the benchmark. Trading was choppy: it opened Monday at $207.68 and touched a weekly high of $210.27, then slid through Tuesday and Wednesday. Thursday brought the sharpest leg down, with the low at $180.49, before a modest bounce on Friday to close at $189.76. Weekly amplitude came to 14.34%.

## Key Events

The company’s main news was the 5 October announcement that it started a Phase 3 trial, RASolute 309, for the daraxonrasib and zoldonrasib combination in first-line metastatic RAS G12D pancreatic cancer. In parallel, sector sentiment softened. Biotech stocks tumbled on 7 October, with recent winners Moderna and Vaxcyte among the biggest losers. Revolution Medicines dropped more than 8% intraday on 8 October and extended losses past 10%, with pancreatic cancer drug data concerns continuing to weigh on the stock into 9 October.

## Analyst Ratings

Among 24 institutions covering the stock, 18 rate it buy, 5 rate it overweight, and 1 rates it hold, with no underweight or sell ratings. The consensus rating is strong buy. The consensus target price is about $259.14, roughly 36.56% above the current price. The target range is wide, from $179 to $320, pointing to notable disagreement. Within 508 names in the biotech sector, the stock ranks 16th by analyst rating.

## The Week Ahead

The macro calendar is relatively busy next week. US CPI and core CPI are due on 14 October, with CPI at a prior 3.4 against a forecast of 3.7, and core CPI at a prior 2.4 against 2.5. NFIB small business sentiment and existing home sales are scheduled for 13 October. On the company side, updates on enrolment and further read-throughs from pancreatic cancer drug data could keep RASolute 309 in focus.

## In Short

The tension this week is between a Phase 3 start and a mostly buy-rated analyst base on one side, and a sharp sell-off driven by biotech weakness and pancreatic cancer data concerns on the other. The stock fell nearly 10% relative to the S&P 500. In the latest trading day, small and medium orders were net buyers while large-lot inflow was modest. The next watch points are CPI data and any fresh signals from RASolute 309.

*This article is generated by LongbridgeAI from market data, for information only and not investment advice.*

### Related Stocks

- [RVMD.US](https://longbridge.com/en/quote/RVMD.US.md)

## Related News & Research

- [Revolution's Rasonque improves survival across subgroups in pancreatic cancer patients](https://longbridge.com/en/news/302871272.md)
- [CHMP backs RASONQUE for metastatic pancreatic cancer](https://longbridge.com/en/news/302430051.md)
- [Revolution Medicines Stock Has Surged 124% This Year — Analyst Sees More Room to Grow](https://longbridge.com/en/news/302133668.md)
- [EMA panel backs approval of Revolution's pancreatic cancer drug](https://longbridge.com/en/news/301989469.md)
- [Binance co-CEO Richard Teng says hackers used fake job interviews, AI tool to steal $6.3 billion in crypto 108511116](https://longbridge.com/en/news/304145542.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**